Hyperlipidemia as a risk factor for progression of CKD in nondiabetics

Dyslipidemias in Kidney Disease

Volumn , Issue , 2014, Pages 27-44

  Kujawa Szewieczek, Agata ^a   Piecha, Grzegorz ^a   Więcek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939986963     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0515-7_3     Document Type: Chapter

References (104)

1. Kujawa-Szewieczek A, Więcek A, Piecha G. The lipid story in chronic kidney disease: a long story with a happy end? Int Urol Nephrol. 2013;45(5):1273–87.
2. Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol. 1999;12:33–40.
3. Cormack-Aboud FC, Brinkkoetter PT, Pippin JW, Shankland SJ, Durvasula RV. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant. 2009;24:404–12.
4. Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Takeuchi S, Tomioka M, et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol Dial Transplant. 2009;24:2378–83.
5. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol. 2005;16:1936–47.
6. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol. 2007;170:1165–77.
7. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–34.
8. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–9.
9. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–8.
10. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a metaanalysis. J Am Soc Nephrol. 2006;17:2006–16.
11. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9–17.
12. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol. 2008;21: 635–44.
13. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant. 1998;13:2833–41.
14. Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int. 2003;63:2171–7.
15. Nishizawa Y, Shoji T, Kawagishi T, Morii H. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl. 1997;62:90–2.
16. Arnadottir M, Nilsson-Ehle P. Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? Nephrol Dial Transplant. 1995;10:2381–2.
17. Vaziri ND, Liang K. Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int. 1997;51:913–9.
18. Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028–32.
19. Heeringa P, Tervaert JW. Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens. 2002;11:287–93.
20. Kasahara J, Kobayashi K, Maeshima Y, Yamasaki Y, Yasuda T, Matsuura E, et al. Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract. 2004;98:15–24.
21. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.
22. O’Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end- stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis. 1996;27:84–91.
23. Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L, Valente M, et al. Lecithincholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978; 13:26–30.
24. McLeod R, Reeve CE, Frohlich J. Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int. 1984;25:683–8.
25. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:262–72.
26. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:1462–6.
27. Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323:579–84.
28. Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int. 2003;63:1756–63.
29. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003;63:1964–76.
30. Kashyap ML, Srivastava LS, Hynd BA, Brady D, Perisutti G, Glueck CJ, et al. Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis. 1980;35:29–40.
31. Vaziri ND, Kim CH, Phan D, Kim S, Liang K. Up-regulation of hepatic acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int. 2004; 66:262–7.
32. Ohta T, Matsuda I. Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta. 1981;117:133–43.
33. Alexander JH, Schapel GJ, Edwards KD. Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust. 1974;2:119–22.
34. Joven J, Rubiés-Prat J, Espinel E, Ras MR, Piera L. High-density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrol Dial Transplant. 1987;2:149–53.
35. Cheung AK, Wu LL, Kablitz C, Leypoldt JK. Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis. 1993;22:271–6.
36. Rapoport J, Aviram M, Chaimovitz C, Brook JG. Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med. 1978;299:1326–9.
37. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemiarelation to renal function and dialysis. Nephron. 1991;57:401–10.
38. Näsström B, Stegmayr B, Olivecrona G, Olivecrona T. Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol. 2004;5:17.
39. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol. 1995;5:1703–8.
40. Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int. 1999;55:1536–42.
41. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, König P, Auinger M, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl. 2003;84:113–6.
42. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–20.
43. Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C, et al. Dyslipidemia in peritoneal dialysis—relation to dialytic variables. Perit Dial Int. 2000;20:306–14.
44. Prinsen BH, Rabelink TJ, Romijn JA, Bisschop PH, de Barse MM, de Boer J, et al. A broadbased metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int. 2004;65:1064–75.
45. Steele J, Billington T, Janus E, Moran J. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis. 1989;79:47–50.
46. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309–11.
47. Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl. 1999;71:62–5.
48. Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep. 2012;14:177–81.
49. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004;13:93–9.
50. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, and p22phox. J Am Soc Nephrol. 1995;5:1483–91.
51. Galle J, Heermeier K. Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress. Nephrol Dial Transplant. 1999;14:2585–9.
52. Lee HS, Song CY. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am J Nephrol. 2009;29:62–70.
53. Park SY, Song CY, Kim BC, Hong HK, Lee HS. Angiotensin II mediates LDL-induced superoxide generation in mesangial cells. Am J Physiol Renal Physiol. 2003;285:909–15.
54. Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int. 1998;54:848–56.
55. Lee HS, Kim BC, Kim YS, Choi KH, Chung HK. Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells. Kidney Int. 1996;50:1582–90.
56. Nishida Y, Yorioka N, Oda H, Yamakido M. Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis. 1997;29:919–30.
57. Kamanna VS, Pai R, Roh DD, Kirschenbaum MA. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab Invest. 1996;74:1067–79.
58. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 1993;43:218–25.
59. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O’Donnell MP. Low-density lipoprotein- induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536–40.
60. Ding G, Pesek-Diamond I, Diamond JR. Cholesterol, macrophages, and gene expression of TGF-1 and fibronectin during nephrosis. Am J Physiol. 1993;33:577–84.
61. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int. 1996;50:1139–49.
62. Lee HS, Kim BC, Hong HK, Kim YS. LDL stimulates collagen mRNA synthesis in mesangial cells through induction of PKC and TGF expression. Am J Physiol. 1999;277:369–76.
63. Song CY, Kim BC, Hong HK, Lee HS. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF signalling in mesangial cells. Kidney Int. 2005;67:1743–52.
64. Ding G, van Goor H, Ricardo SD, Orlowski JM, Diamond JR. Oxidized LDL stimulates the expression of TGF and fibronectin inhuman glomerular epithelial cells. Kidney Int. 1997;51:147–54.
65. Hong HK, Song CY, Kim BC, Lee HS. ERK contributes to the effects of Smad signalling on oxidized LDL-induced PAI-1 expression in human mesangial cells. Transl Res. 2006;148: 171–9.
66. Sohn M, Tan Y, Klein RL, Jaffa AA. Evidence for low-density lipoprotein-induced expression of connective tissue growth factor in mesangial cells. Kidney Int. 2005;67:1286–96.
67. Harada-Shiba M, Kinoshita M, Kamido H, Shimokado KJ. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. Biol Chem. 1998;273:9681–7.
68. Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int. 1999;55:1450–61.
69. Sharma P, Reddy K, Franki N, Sanwal V, Sankaran R, Ahuja TS, et al. Native and oxidized low density lipoproteins modulate mesangial cell apoptosis. Kidney Int. 1996;50:1604–11.
70. Agarwal A, Balla J, Balla G, Croatt AJ, Vercellotti GM, Nath KA. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol. 1996;271:814–23.
71. Keil A, Blom IE, Goldschmeding R, Rupprecht HD. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int. 2002;62:401–11.
72. Wu ZL, Liang MY, Qiu LQ. Oxidized low-density lipoprotein decreases the induced nitric oxide synthesis in rat mesangial cells. Cell Biochem Funct. 1998;16:153–8.
73. Hein TW, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res. 1998;83:404–14.
74. Tan MS, Lee YJ, Shin SJ, Tsai JH. Oxidized low-density lipoprotein stimulates endothelin-1 release and mRNA expression from rat mesangial cells. J Lab Clin Med. 1997;129:224–30.
75. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:2–5.
76. Galle J, Heinloth A, Schwedler S, Wanner C. Effect of HDL and atherogenic lipoproteins on formation of O2–and renin release in juxtaglomerular cells. Kidney Int. 1997;51:253–60.
77. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908–15.
78. Lynn EG, Siow YL, O K. Very low-density lipoprotein stimulates the expression of monocyte chemoattractant protein-1 in mesangial cells. Kidney Int. 2000;57:1472–83.
79. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11:669–83.
80. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl. 1999;71:47–50.
81. Jayapalan S, Saboorian MH, Edmunds JW, Aukema HM. High dietary fat intake increases renal cyst disease progression in Han:SPRD-cy rats. J Nutr. 2000;130:2356–60.
82. Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int. 1993;43:918–27.
83. Ozsoy RC, van der Steeg WA, Kastelein JJ, Arisz L, Koopman MG. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant. 2007;22:1578–86.
84. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14: 2084–91.
85. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670–5.
86. Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) study. J Atheroscler Thromb. 2010;17:601–9.
87. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.
88. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55:1266–73.
89. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412–24.
90. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006;21:3106–14.
91. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebocontrolled trial. Lancet. 2003;361:2024–31.
92. Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–36.
93. Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Hörl WH, Oberbauer R. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol. 2008;19:2211–8.
94. de Zeeuw. Prospective evaluation of proteinuria and renal function in nondiabetic patients with progressive renal disease: XLVII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) congress 2010, June 25–28, Munich, Germany
95. Abe M, Maruyama N, Yoshida Y, Ito M, Okada K, Soma M. Efficacy analysis of the lipidlowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr J. 2011;58:663–74.
96. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2004;41:565–70.
97. Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L. The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis. Clin Nephrol. 2005;63:245–9.
98. Deslypere JP, Delanghe J, Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet. 1990;336:1453.
99. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111:219–28.
100. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology. 2007;107:433–43.
101. Kostapanos MS, Milionis HJ, Gazi I, Kostara C, Bairaktari ET, Elisaf M. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol. 2006;46:1337–43.
102. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260–9.
103. Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145:117–24.
104. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;2:CD007784.